Compare MLKN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | CMPX |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 927.5M |
| IPO Year | 1994 | 2020 |
| Metric | MLKN | CMPX |
|---|---|---|
| Price | $14.70 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 624.6K | ★ 12.2M |
| Earning Date | 03-25-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.78 | $934.41 |
| P/E Ratio | $14.80 | ★ N/A |
| Revenue Growth | ★ 1.14 | N/A |
| 52 Week Low | $13.77 | $1.61 |
| 52 Week High | $23.18 | $6.88 |
| Indicator | MLKN | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 26.23 |
| Support Level | $13.81 | $1.61 |
| Resistance Level | $16.34 | $3.54 |
| Average True Range (ATR) | 0.59 | 0.15 |
| MACD | -0.14 | 0.06 |
| Stochastic Oscillator | 9.63 | 46.05 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.